CGC Genomics raises 1.7 million euros

CGC Genomics develops Qnomx, an AI solution for cancer diagnostics, and secures financing of 1.7 million euros for clinical trials and market entry.

Basel, April 14, 2025 - The Swiss HealthTech startup CGC Genomics has raised 1.7 million euros. The company intends to use the fresh capital to further develop its GenAI platform Qnomx. The aim is to facilitate the interpretation of cancer genome data. Investors include Heal Capital, better ventures and Becker Ventures.

Major hurdles in the interpretation of cancer data

Cancer is on the rise worldwide. More than 20 million new cases were registered in 2022 alone. The analysis of tumor genomes is important for targeted treatment. This is usually done using next generation sequencing (NGS) methods.

However, although guidelines recommend the use of NGS, only 20 to 30 percent of patients receive a corresponding analysis. Many oncologists find the reports too complex. This makes it difficult to make a reliable treatment decision. Around 80 percent of the doctors surveyed reported that interpreting the data requires a lot of time and specialist knowledge.

Qnomx aims to simplify evaluation

This is where Qnomx comes in. The AI-based platform processes the results of genetic analyses. It creates clinically relevant and easy-to-understand summaries. Instead of two hours, the analysis now only takes a few minutes. Initial internal tests show significant efficiency gains. These are now being tested in pilot projects with Labor Becker and the OnkoMedeor Group.

Diagnostics scales - but interpretation does not. This is exactly what we are changing with Qnomx

Dr. Joerg Hoelzing, Co-CEO of CGC Genomics

Qnomx offers the summaries in the respective national language. A human remains involved at all times as a control instance ("human in the loop").

Regulated AI solution from Europe

CGC Genomics intends to launch Qnomx on the market as the first medically certified generative AI solution for cancer diagnostics. To this end, the company is complying with European regulations such as IVDR, MDR and the new AI Act.

The platform is being developed under an ISO 13485-certified quality management system. Qnomx is therefore intended to offer a tested alternative to unregulated AI tools such as ChatGPT, some of which are already being used in clinics. James Creeden, also Co-CEO of CGC Genomics, emphasizes: "With Qnomx, we enable more precise therapies and at the same time relieve the burden on medical staff."

Investors focus on precision medicine

The capital from the pre-seed round will be used for clinical validation, market entry and international expansion. In addition to Heal Capital and better ventures, Springboard Health Angels, Superangels and Becker Ventures are also participating.

Artificial intelligence will change the healthcare sector - but only if it is regulated and used responsibly. CGC Genomics shows how this can be done.

Tina Dreimann from better ventures

Christian Lautner from Heal Capital explains: "Qnomx addresses a key challenge: making genomic data truly usable." Marc Becker, Managing Director of Labor Becker, also praises the platform: "The collaboration with CGC Genomics will further increase the efficiency and quality of our NGS process."

Experienced team

CGC Genomics was founded in 2023. The founding team brings together expertise in medicine, artificial intelligence and business management. James Creeden previously held senior positions at Roche and Foundation Medicine. Joerg Hoelzing gained experience at Roche Diagnostics and mySugr, among others. Marcus Olivecrona joined the team as CTO in April 2025. He brings expertise from the AI development of medical software.